Abstract:Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection (LRTI), hospitalization, and mortality in infants and young children globally. The greatest burden of severe disease and mortality occurs in low‐middle income countries (LMICs), with large and vulnerable childhood populations. The highest rates of RSV‐hospitalization occur in healthy‐term infants under 3 months of age. Preterm infants, children with chronic lung disease of prematurity, Down's syndrome, congenital heart disease, or immunodeficiency also have a higher risk of severe RSV‐LRTI. Early‐life RSV‐LRTI has also been associated with chronic sequelae, including recurrent LRTI, recurrent wheezing, asthma, and lung function impairment. A RSV pre‐fusion (F) maternal vaccine and long‐acting monoclonal antibody (nirsevimab) have been licensed for the prevention of RSV‐LRTI in infants and young children. Studies show high efficacy and effectiveness particularly for preventing severe RSV‐LRTI. Maternal RSV vaccine given at 24–36 weeks of pregnancy was effective in preventing RSV medically attended LRTI and severe RSV‐LRTI through 6 months after birth in a phase 3 study conducted in 18 countries over two RSV seasons. Vaccination was safe with no significant difference in adverse events between infants born to mothers who received RSV preF vaccine compared to placebo. A numerical imbalance in preterm births that occurred predominantly in South Africa, unrelated to vaccine timing or gestational age at vaccination and unassociated with mortality, coincided with COVID‐19 delta and omicron waves. Nirsevimab, given as a single dose prior or during the RSV season, had high efficacy in preventing RSV‐LRTI hospitalization in infants in preterm and in full‐term infants, as well as in young children with underlying conditions through 150 days post administration in phase 2 and 3 trials. High effectiveness against hospitalization or severe disease in infants and in at‐risk children up to 2 years of age has also been reported in several countries where implementation has occurred. RSV‐LRTI is now a preventable disease in infants and young children. Rapid implementation of these highly effective interventions has occurred in many high‐income countries, but access remains very limited in LMICs. Access to such RSV preventive interventions is urgently needed for all children to strengthen child health and promote global equity.

Family and Child Risk Factors for Early-Life RSV Illness

Neighbourhood-level burden of social risk factors on respiratory syncytial virus hospitalization in Ontario, Canada, 2016-2019

Respiratory Syncytial Virus Hospitalizations Associated with Social Vulnerability by Census Tract: An Opportunity for Intervention?

Socioeconomic Impact of RSV Hospitalization

Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis

Parental Socioeconomic Status and an Infant’s Risk of Hospital Admission for RSV

2629. Respiratory Syncytial Virus Epidemiology and Factors Associated with Severity among Hospitalized Infants in Four Middle-Income Countries, 2015–2017

Respiratory Syncytial Virus-Associated Hospitalizations Among Children <5 Years Old: 2016 to 2020

Respiratory Syncytial Virus–Associated Hospitalizations Among Young Children: 2015–2016

Parental Socioeconomic Status and an Infant's Risk of Hospital Admission for RSV

Risk Factors and Clinical Prognosis Associated With RSV-ALRI Intensive Care Unit Admission in Children <2 Years of Age: A Multicenter Study

Age‐specific predictors of disease severity in children with respiratory syncytial virus infection beyond infancy and through the first 5 years of age

Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children

Early-life respiratory syncytial virus disease and long-term respiratory health

Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy

Risk Factors for Severe Respiratory Syncytial Virus Infection in Hospitalized Children

Risk factors for severe disease in pediatric respiratory syncytial virus infections

New advances in RSV: Is prevention attainable?

Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review

Impact of respiratory syncytial virus on older children: Exploring the potential for preventive strategies beyond the age of 2 years

Adult Respiratory Syncytial Virus Infection: Defining Incidence, Risk Factors for Hospitalization, and Poor Outcomes, a Regional Cohort Study, 2016–2022